GrippeAllemagneV4, Main, Exploration, bibRecord, 000095

Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Identifieur interne : 000095 ( Main/Exploration ); précédent : 000094; suivant : 000096

Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Auteurs : Ulrich Behre [Allemagne] ; Olivier Van Der Meeren [Belgique] ; Priya Crasta [Inde] ; Linda Hanssens [Belgique] ; Narcisa Mesaros [Belgique]

Source :

Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.

RBID : pubmed:27653771

Descripteurs français

English descriptors

KwdEn :
- Adolescent (MeSH), Age Factors (MeSH), Child (MeSH), Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage), Diphtheria-Tetanus-Pertussis Vaccine (immunology), Female (MeSH), Germany (MeSH), Haemophilus Vaccines (administration & dosage), Haemophilus Vaccines (immunology), Hepatitis B (prevention & control), Hepatitis B Antibodies (blood), Hepatitis B Vaccines (administration & dosage), Hepatitis B Vaccines (immunology), Humans (MeSH), Immunologic Memory (MeSH), Male (MeSH), Poliovirus Vaccine, Inactivated (administration & dosage), Poliovirus Vaccine, Inactivated (immunology), Vaccines, Combined (administration & dosage), Vaccines, Combined (immunology).
MESH :
- chemical , administration & dosage : Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Vaccines, Hepatitis B Vaccines, Poliovirus Vaccine, Inactivated, Vaccines, Combined.
- chemical , blood : Hepatitis B Antibodies.
- chemical , immunology : Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Vaccines, Hepatitis B Vaccines, Poliovirus Vaccine, Inactivated, Vaccines, Combined.
- prevention & control : Hepatitis B.
- Adolescent, Age Factors, Child, Female, Germany, Humans, Immunologic Memory, Male.

Abstract

BACKGROUND

Vaccinating infants against hepatitis B virus (HBV) is the most effective way of preventing the disease. However, since HBV exposure can increase during adolescence, it is essential that antibody persistence is maintained. We evaluated the antibody persistence and immune memory against hepatitis B, in 12-13 y olds who had received complete primary + booster vaccination with diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/Haemophilus influenza type b (DTPa-HBV-IPV/Hib) vaccine in infancy.

METHODS

Open phase-IV study conducted at 12 centers in Germany [NCT02052661]. Adolescents aged 12-13 y, vaccinated with 4 doses of DTPa-HBV-IPV/Hib (Infanrix hexa™, GSK Vaccines) in infancy, received a single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines). Blood samples were taken before and 1-month post-challenge to measure anti-hepatitis B (anti-HBs) antibodies using a chemiluminescence immunoassay (seroprotection cut-off: ≥10 mIU/ml). Post-challenge adverse events (AEs) were monitored.

RESULTS

300 subjects were vaccinated; of 293 subjects in the ATP immunogenicity cohort, 60.5% had pre-challenge anti-HBs antibodies ≥10 mIU/ml, which rose to 97.6% post-challenge (≥100 mIU/ml in 94.1%). An anamnestic response was seen in 96.5% subjects. A 150-fold increase in antibody geometric mean concentrations was observed (22.4 to 3502.6 mIU/ml). Pain (44%) and fatigue (24.3%) were the most frequent solicited local and general AEs, respectively; 14.7% subjects reported unsolicited symptoms during the 31-day post-vaccination period. Two vaccine-unrelated serious AEs occurred.

CONCLUSION

Vaccination with DTPa-HBV-IPV/Hib in infancy induces sustained seroprotection and immune memory against HBV, as shown by the strong anamnestic response to the hepatitis B vaccine challenge in 12-13 year-old adolescents.

DOI: 10.1080/21645515.2016.1202388
PubMed: 27653771
PubMed Central: PMC5137516

Affiliations:

Allemagne, Belgique, Inde

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000081
to stream Main, to step Curation: 000081

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.</title>
<author><name sortKey="Behre, Ulrich" sort="Behre, Ulrich" uniqKey="Behre U" first="Ulrich" last="Behre">Ulrich Behre</name>
<affiliation wicri:level="1"><nlm:affiliation>a Pediatric Practice , Kehl , Baden-Württemberg , Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>a Pediatric Practice , Kehl , Baden-Württemberg </wicri:regionArea>
<wicri:noRegion>Baden-Württemberg </wicri:noRegion>
<wicri:noRegion>Baden-Württemberg </wicri:noRegion>
<wicri:noRegion>Baden-Württemberg </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Der Meeren, Olivier" sort="Van Der Meeren, Olivier" uniqKey="Van Der Meeren O" first="Olivier" last="Van Der Meeren">Olivier Van Der Meeren</name>
<affiliation wicri:level="1"><nlm:affiliation>b GSK Vaccines , Wavre , Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>b GSK Vaccines , Wavre </wicri:regionArea>
<wicri:noRegion>Wavre </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crasta, Priya" sort="Crasta, Priya" uniqKey="Crasta P" first="Priya" last="Crasta">Priya Crasta</name>
<affiliation wicri:level="1"><nlm:affiliation>c GSK Vaccines , Bangalore , India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>c GSK Vaccines , Bangalore </wicri:regionArea>
<wicri:noRegion>Bangalore </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hanssens, Linda" sort="Hanssens, Linda" uniqKey="Hanssens L" first="Linda" last="Hanssens">Linda Hanssens</name>
<affiliation wicri:level="1"><nlm:affiliation>b GSK Vaccines , Wavre , Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>b GSK Vaccines , Wavre </wicri:regionArea>
<wicri:noRegion>Wavre </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mesaros, Narcisa" sort="Mesaros, Narcisa" uniqKey="Mesaros N" first="Narcisa" last="Mesaros">Narcisa Mesaros</name>
<affiliation wicri:level="1"><nlm:affiliation>b GSK Vaccines , Wavre , Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>b GSK Vaccines , Wavre </wicri:regionArea>
<wicri:noRegion>Wavre </wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27653771</idno>
<idno type="pmid">27653771</idno>
<idno type="doi">10.1080/21645515.2016.1202388</idno>
<idno type="pmc">PMC5137516</idno>
<idno type="wicri:Area/Main/Corpus">000081</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000081</idno>
<idno type="wicri:Area/Main/Curation">000081</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000081</idno>
<idno type="wicri:Area/Main/Exploration">000081</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.</title>
<author><name sortKey="Behre, Ulrich" sort="Behre, Ulrich" uniqKey="Behre U" first="Ulrich" last="Behre">Ulrich Behre</name>
<affiliation wicri:level="1"><nlm:affiliation>a Pediatric Practice , Kehl , Baden-Württemberg , Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>a Pediatric Practice , Kehl , Baden-Württemberg </wicri:regionArea>
<wicri:noRegion>Baden-Württemberg </wicri:noRegion>
<wicri:noRegion>Baden-Württemberg </wicri:noRegion>
<wicri:noRegion>Baden-Württemberg </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Der Meeren, Olivier" sort="Van Der Meeren, Olivier" uniqKey="Van Der Meeren O" first="Olivier" last="Van Der Meeren">Olivier Van Der Meeren</name>
<affiliation wicri:level="1"><nlm:affiliation>b GSK Vaccines , Wavre , Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>b GSK Vaccines , Wavre </wicri:regionArea>
<wicri:noRegion>Wavre </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crasta, Priya" sort="Crasta, Priya" uniqKey="Crasta P" first="Priya" last="Crasta">Priya Crasta</name>
<affiliation wicri:level="1"><nlm:affiliation>c GSK Vaccines , Bangalore , India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>c GSK Vaccines , Bangalore </wicri:regionArea>
<wicri:noRegion>Bangalore </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hanssens, Linda" sort="Hanssens, Linda" uniqKey="Hanssens L" first="Linda" last="Hanssens">Linda Hanssens</name>
<affiliation wicri:level="1"><nlm:affiliation>b GSK Vaccines , Wavre , Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>b GSK Vaccines , Wavre </wicri:regionArea>
<wicri:noRegion>Wavre </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mesaros, Narcisa" sort="Mesaros, Narcisa" uniqKey="Mesaros N" first="Narcisa" last="Mesaros">Narcisa Mesaros</name>
<affiliation wicri:level="1"><nlm:affiliation>b GSK Vaccines , Wavre , Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>b GSK Vaccines , Wavre </wicri:regionArea>
<wicri:noRegion>Wavre </wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Age Factors (MeSH)</term>
<term>Child (MeSH)</term>
<term>Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage)</term>
<term>Diphtheria-Tetanus-Pertussis Vaccine (immunology)</term>
<term>Female (MeSH)</term>
<term>Germany (MeSH)</term>
<term>Haemophilus Vaccines (administration & dosage)</term>
<term>Haemophilus Vaccines (immunology)</term>
<term>Hepatitis B (prevention & control)</term>
<term>Hepatitis B Antibodies (blood)</term>
<term>Hepatitis B Vaccines (administration & dosage)</term>
<term>Hepatitis B Vaccines (immunology)</term>
<term>Humans (MeSH)</term>
<term>Immunologic Memory (MeSH)</term>
<term>Male (MeSH)</term>
<term>Poliovirus Vaccine, Inactivated (administration & dosage)</term>
<term>Poliovirus Vaccine, Inactivated (immunology)</term>
<term>Vaccines, Combined (administration & dosage)</term>
<term>Vaccines, Combined (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Allemagne (MeSH)</term>
<term>Anticorps de l'hépatite B (sang)</term>
<term>Enfant (MeSH)</term>
<term>Facteurs âges (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hépatite B (prévention et contrôle)</term>
<term>Mâle (MeSH)</term>
<term>Mémoire immunologique (MeSH)</term>
<term>Vaccin antipoliomyélitique inactivé (administration et posologie)</term>
<term>Vaccin antipoliomyélitique inactivé (immunologie)</term>
<term>Vaccin diphtérie-tétanos-coqueluche (administration et posologie)</term>
<term>Vaccin diphtérie-tétanos-coqueluche (immunologie)</term>
<term>Vaccins anti-Haemophilus (administration et posologie)</term>
<term>Vaccins anti-Haemophilus (immunologie)</term>
<term>Vaccins anti-hépatite B (administration et posologie)</term>
<term>Vaccins anti-hépatite B (immunologie)</term>
<term>Vaccins combinés (administration et posologie)</term>
<term>Vaccins combinés (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term>
<term>Haemophilus Vaccines</term>
<term>Hepatitis B Vaccines</term>
<term>Poliovirus Vaccine, Inactivated</term>
<term>Vaccines, Combined</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Hepatitis B Antibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term>
<term>Haemophilus Vaccines</term>
<term>Hepatitis B Vaccines</term>
<term>Poliovirus Vaccine, Inactivated</term>
<term>Vaccines, Combined</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccin antipoliomyélitique inactivé</term>
<term>Vaccin diphtérie-tétanos-coqueluche</term>
<term>Vaccins anti-Haemophilus</term>
<term>Vaccins anti-hépatite B</term>
<term>Vaccins combinés</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccin antipoliomyélitique inactivé</term>
<term>Vaccin diphtérie-tétanos-coqueluche</term>
<term>Vaccins anti-Haemophilus</term>
<term>Vaccins anti-hépatite B</term>
<term>Vaccins combinés</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis B</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Hépatite B</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps de l'hépatite B</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Age Factors</term>
<term>Child</term>
<term>Female</term>
<term>Germany</term>
<term>Humans</term>
<term>Immunologic Memory</term>
<term>Male</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Allemagne</term>
<term>Enfant</term>
<term>Facteurs âges</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Mémoire immunologique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Vaccinating infants against hepatitis B virus (HBV) is the most effective way of preventing the disease. However, since HBV exposure can increase during adolescence, it is essential that antibody persistence is maintained. We evaluated the antibody persistence and immune memory against hepatitis B, in 12-13 y olds who had received complete primary + booster vaccination with diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/Haemophilus influenza type b (DTPa-HBV-IPV/Hib) vaccine in infancy.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Open phase-IV study conducted at 12 centers in Germany [NCT02052661]. Adolescents aged 12-13 y, vaccinated with 4 doses of DTPa-HBV-IPV/Hib (Infanrix hexa™, GSK Vaccines) in infancy, received a single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines). Blood samples were taken before and 1-month post-challenge to measure anti-hepatitis B (anti-HBs) antibodies using a chemiluminescence immunoassay (seroprotection cut-off: ≥10 mIU/ml). Post-challenge adverse events (AEs) were monitored.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>300 subjects were vaccinated; of 293 subjects in the ATP immunogenicity cohort, 60.5% had pre-challenge anti-HBs antibodies ≥10 mIU/ml, which rose to 97.6% post-challenge (≥100 mIU/ml in 94.1%). An anamnestic response was seen in 96.5% subjects. A 150-fold increase in antibody geometric mean concentrations was observed (22.4 to 3502.6 mIU/ml). Pain (44%) and fatigue (24.3%) were the most frequent solicited local and general AEs, respectively; 14.7% subjects reported unsolicited symptoms during the 31-day post-vaccination period. Two vaccine-unrelated serious AEs occurred.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Vaccination with DTPa-HBV-IPV/Hib in infancy induces sustained seroprotection and immune memory against HBV, as shown by the strong anamnestic response to the hepatitis B vaccine challenge in 12-13 year-old adolescents.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27653771</PMID>
<DateCompleted><Year>2017</Year>
<Month>10</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>12</Volume>
<Issue>11</Issue>
<PubDate><Year>2016</Year>
<Month>11</Month>
</PubDate>
</JournalIssue>
<Title>Human vaccines & immunotherapeutics</Title>
<ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
</Journal>
<ArticleTitle>Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.</ArticleTitle>
<Pagination><MedlinePgn>2916-2920</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND">Vaccinating infants against hepatitis B virus (HBV) is the most effective way of preventing the disease. However, since HBV exposure can increase during adolescence, it is essential that antibody persistence is maintained. We evaluated the antibody persistence and immune memory against hepatitis B, in 12-13 y olds who had received complete primary + booster vaccination with diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/Haemophilus influenza type b (DTPa-HBV-IPV/Hib) vaccine in infancy.</AbstractText>
<AbstractText Label="METHODS">Open phase-IV study conducted at 12 centers in Germany [NCT02052661]. Adolescents aged 12-13 y, vaccinated with 4 doses of DTPa-HBV-IPV/Hib (Infanrix hexa™, GSK Vaccines) in infancy, received a single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines). Blood samples were taken before and 1-month post-challenge to measure anti-hepatitis B (anti-HBs) antibodies using a chemiluminescence immunoassay (seroprotection cut-off: ≥10 mIU/ml). Post-challenge adverse events (AEs) were monitored.</AbstractText>
<AbstractText Label="RESULTS">300 subjects were vaccinated; of 293 subjects in the ATP immunogenicity cohort, 60.5% had pre-challenge anti-HBs antibodies ≥10 mIU/ml, which rose to 97.6% post-challenge (≥100 mIU/ml in 94.1%). An anamnestic response was seen in 96.5% subjects. A 150-fold increase in antibody geometric mean concentrations was observed (22.4 to 3502.6 mIU/ml). Pain (44%) and fatigue (24.3%) were the most frequent solicited local and general AEs, respectively; 14.7% subjects reported unsolicited symptoms during the 31-day post-vaccination period. Two vaccine-unrelated serious AEs occurred.</AbstractText>
<AbstractText Label="CONCLUSION">Vaccination with DTPa-HBV-IPV/Hib in infancy induces sustained seroprotection and immune memory against HBV, as shown by the strong anamnestic response to the hepatitis B vaccine challenge in 12-13 year-old adolescents.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Behre</LastName>
<ForeName>Ulrich</ForeName>
<Initials>U</Initials>
<AffiliationInfo><Affiliation>a Pediatric Practice , Kehl , Baden-Württemberg , Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Der Meeren</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>b GSK Vaccines , Wavre , Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Crasta</LastName>
<ForeName>Priya</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>c GSK Vaccines , Bangalore , India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hanssens</LastName>
<ForeName>Linda</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>b GSK Vaccines , Wavre , Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mesaros</LastName>
<ForeName>Narcisa</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>b GSK Vaccines , Wavre , Belgium.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>09</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hum Vaccin Immunother</MedlineTA>
<NlmUniqueID>101572652</NlmUniqueID>
<ISSNLinking>2164-5515</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C541235">diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018073" MajorTopicYN="N">Haemophilus Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adolescents</Keyword>
<Keyword MajorTopicYN="Y">DTPa-HBV-IPV/Hib</Keyword>
<Keyword MajorTopicYN="Y">anamnestic response</Keyword>
<Keyword MajorTopicYN="Y">challenge dose</Keyword>
<Keyword MajorTopicYN="Y">hepatitis B</Keyword>
<Keyword MajorTopicYN="Y">immune memory</Keyword>
<Keyword MajorTopicYN="Y">long-term</Keyword>
<Keyword MajorTopicYN="Y">persistence</Keyword>
<Keyword MajorTopicYN="Y">seroprotection</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27653771</ArticleId>
<ArticleId IdType="doi">10.1080/21645515.2016.1202388</ArticleId>
<ArticleId IdType="pmc">PMC5137516</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2009 Jun;8(6):663-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19485747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2014;10(6):1682-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24637296</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BioDrugs. 2010 Oct 1;24(5):299-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20795752</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2003;63(10):1021-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12699402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jan 22;25(6):1055-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17049692</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 May 28;33(23):2727-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24962750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Nov 1;200(9):1390-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19785526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2013 Aug;9(8):1679-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23732904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2015 Oct 17;386(10003):1546-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26231459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Jan 8;28(3):730-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19892043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2010 Jan 15;10:9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20078876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin. 2009 Sep;5(9):592-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19535920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2005 Oct 15-21;366(9494):1379-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16226616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2010 Nov;138(11):1621-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20233496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2012 Jun;8(6):813-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22508412</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Belgique</li>
<li>Inde</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Behre, Ulrich" sort="Behre, Ulrich" uniqKey="Behre U" first="Ulrich" last="Behre">Ulrich Behre</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Van Der Meeren, Olivier" sort="Van Der Meeren, Olivier" uniqKey="Van Der Meeren O" first="Olivier" last="Van Der Meeren">Olivier Van Der Meeren</name>
</noRegion>
<name sortKey="Hanssens, Linda" sort="Hanssens, Linda" uniqKey="Hanssens L" first="Linda" last="Hanssens">Linda Hanssens</name>
<name sortKey="Mesaros, Narcisa" sort="Mesaros, Narcisa" uniqKey="Mesaros N" first="Narcisa" last="Mesaros">Narcisa Mesaros</name>
</country>
<country name="Inde"><noRegion><name sortKey="Crasta, Priya" sort="Crasta, Priya" uniqKey="Crasta P" first="Priya" last="Crasta">Priya Crasta</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000095 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000095 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeAllemagneV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27653771
   |texte=   Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27653771" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 17:53:30 2020. Site generation: Sat Mar 27 17:40:37 2021

	Serveur d'exploration sur la grippe en Allemagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Allemagne

Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki